Will ustekinumab be included in the national medical insurance directory in the future?

Ustekinumab (Ustekinumab) is a drug that targets interleukin-12 (IL-12) and interleukin-23< /span> (IL-23) shared p40 subunit monoclonal antibody, mainly used to treat moderate to severe plaque psoriasis, Crohn's disease and other immune-mediated chronic inflammatory diseases. Since being included in the national medical insurance directory for the first time in 2021, ustekinumab has been launched in China and included in medical insurance, reducing the financial burden on patients.

The inclusion of ustekinumab in the medical insurance catalog marks the country’s increasing support for innovative drugs. 2021Year1Month1 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2021 Edition) was officially implemented, and ustekinumab, as an innovative biological agent for the treatment of Crohn's disease, was included in the medical insurance catalog for the first time. This move effectively improves drug accessibility for patients, especially for young and middle-aged patients, and reduces the economic burden of long-term treatment.

With the deepening of clinical research, the indications of ustekinumab continue to expand. Ustekinumab is currently approved for the treatment of moderate to severe plaque psoriasis in adults and children, as well as conditions such as Crohn's disease. In addition, in December 2024, the supplementary application for ustekinumab for children with plaque psoriasis was accepted by the National Medical Products Administration (NMPA), further broadening its clinical application scope.

Looking to the future, with the approval of more indications and the accumulation of clinical data, ustekinumab is expected to be applied in more disease areas. The continued optimization of national medical insurance policies and support for innovative drugs are expected to further promote the popularity and application of ustekinumab in the country. Reasonable use of ustekinumab by patients under the guidance of doctors will help improve treatment effects and quality of life.

Reference materials:https://www.drugs.com